Life science titan GE Healthcare (NYSE:GE) landed a win in Europe for its SenoClaire 3D breast imaging system, which the company says exposes women to less radiation during breast cancer screening.
The SenoClaire sweeps around the positioned breast with 9 exposures of low-dose X-ray radiation, an imaging technique that requires only 1 tissue compression and half the radiation exposure of traditional imaging techniques, GE said.
The SenoClaire system features new image reconstruction software called ASiRDBT, which the company said is part of an upgraded solution for its digital mammography devices, the Senographe Essential and Senographe Care.
"We are thrilled to receive the CE marking for this important product in our Women’s Health business. We continue to innovate our portfolio and aim to help clinicians expand care to more women globally in order to help reduce breast cancer," said Prahlad Singh, general manager for GE’s Women’s Health division, in prepared remarks.
GE just announced plans to pour $2 billion into a 5-year program to boost its software for healthcare systems and applications.
